**Online Supplementary Table 4: Summary of protocol deviations (enrolled patients)**

| Type of deviation | Deviation code | Deviation description | Total (N = 941) n (%) |
|---|---|---|---|
| **Inclusion criteria** | IC003 | None of the following conditions was fulfilled: eye(s) eligible for ranibizumab treatment, with a BCVA below 2/10 due to nAMD or - second eye eligible for ranibizumab treatment, with first eye treated (currently or previously) with ranibizumab, regardless of BCVA. In bilateral nAMD patients, the second eye can be included only if the first eye has been treated at least 14 days before with ranibizumab. Patients developing fellow eye nAMD affection (newly diagnosed) while the study is running satisfy the present criterion and are consecutively eligible for enrollment. | 26 (2.8) |
| **Exclusion criteria** | EC003 | Retinal pigment epithelial tear (evidence at time of enrollment) | 26 (2.8) |
| | EC004 | Ocular disorders that may confound interpretation of results compromise visual acuity or require medical or surgical intervention during the study period including mature cataract (instrumental evidence at enrollment), retinal vascular occlusion, preretinal membrane, retinal detachment or macular hole | 29 (3.1) |
| | EC005 | Uncontrolled glaucoma in either eye (IOP ≥30 mmHg on medication or according to investigator's judgment) | 1 (0.1) |
| | EC006 | History of vitrectomy in the study eye | 2 (0.2) |
| | EC009 | Ocular treatment of the study eye with any anti-angiogenic drugs including any anti-VEGF drug, i.e. bevacizumab, aflibercept, pegaptanib, vPDT) within 1 month prior to study enrollment | 3 (0.3) |

| | | | |
|---|---|---|---|
| **Concomitant medication** | CMED3 | Systemic medications known to be toxic to the lens, retina or optic nerve including deferoxamine, chloroquine/hydroxychloroquine (plaquenil®), tamoxifen, phenothiazines, and ethambutol | 1 (0.1) |
| | CMED7 | Any other investigational drug at any time during the study | 1 (0.1) |
| **Treatment withdrawal/interruption** | WITH10 | Any other protocol deviation that resulted in a significant risk to the patient's safety | 3 (0.3) |
| **Protocol procedure** | PROC1 | The duration of the study was greater than 12 months + 7 days per eye | 136 (14.5) |
| | PROC2 | Patient was not contacted by telephone 2 (±1) days following each visit when program drug was administered | 33 (3.5) |
| | PROC3 | IOP not measured prior to ranibizumab dosing and 1 hour post-dose in the study eye(s) | 151 (16.1) |
| | PROC5 | VA assessment was not performed according to protocol at the scheduled visits* | 49 (5.2) |
| | PROC6 | IOP was not measured according to protocol at the scheduled visits | 22 (2.3) |
| | PROC7 | Ocular examination was not performed according to protocol at the scheduled visits | 45 (4.8) |
| **Study drug** | DRUG1 | For patients treated in both eyes, time between injection was less than 14 days | 37 (3.9) |
| | DRUG2 | Procedures for the administration of the drug not met | 169 (18.0) |
| | DRUG3 | Patient was not monitored monthly for visual acuity and treatment | 488 (51.9) |
| | DRUG5 | Investigational treatment not handled and stored properly (including temperature control) | 3 (0.3) |
| | DRUG6 | Subject did not receive at least one dose of study drug† | 5 (0.5) |
| | DRUG7 | Patient administered commercial ranibizumab | 10 (1.1) |

| | | | |
|---|---|---|---|
| | DRUG8 | Time from visit 1 date and date of first administration greater than 7 days | 176 (18.7) |
| **Other** | OTH01 | Written informed consent after study-specific assessment | 21 (2.2) |
| | OTH02 | Subject signed an obsolete version of informed consent | 3 (0.3) |

*Refers to VA assessment not being performed as per label rather than as per protocol. †Exclusion from safety population (exclusion code).

BCVA, best-corrected visual acuity; CMED, concomitant medication; DRUG, study drug; EC, exclusion criteria; IC, inclusion criteria; IOP, intraocular pressure; nAMD, neovascular age-related macular degeneration; OTH, other; PROC, protocol procedure; VA, visual acuity; VEGF, vascular endothelial growth factor; vPDT, verteporfin photodynamic therapy; WITH, treatment withdrawal/interruption.